{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:05:19Z","timestamp":1777352719643,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-15-RHU-0004"],"award-info":[{"award-number":["ANR-15-RHU-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-15-IDEX-04-LUE"],"award-info":[{"award-number":["ANR-15-IDEX-04-LUE"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00392-019-01500-3","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T17:02:45Z","timestamp":1561654965000},"page":"194-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-9377","authenticated-orcid":false,"given":"Susan","family":"Stienen","sequence":"first","affiliation":[]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Barros","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1011119003788","volume":"15","author":"B Pitt","year":"2001","unstructured":"Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 15:79\u201387","journal-title":"Cardiovasc Drugs Ther"},{"key":"1500_CR2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone post-acute myocardial infarction heart failure E and survival study I. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"1500_CR3","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","volume":"58","author":"P Rossignol","year":"2011","unstructured":"Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F (2011) Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (eplerenone post-acute myocardial infarction heart failure efficacy and survival study) substudy. J Am Coll Cardiol 58:1958\u20131966","journal-title":"J Am Coll Cardiol"},{"key":"1500_CR4","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"W Iraqi","year":"2009","unstructured":"Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119:2471\u20132479","journal-title":"Circulation"},{"key":"1500_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","volume":"107","author":"JP Ferreira","year":"2018","unstructured":"Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F (2018) Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clin Res Cardiol 107:49\u201359","journal-title":"Clin Res Cardiol"},{"key":"1500_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s00392-018-1373-5","volume":"107","author":"JP Ferreira","year":"2018","unstructured":"Ferreira JP, Barros A, Pitt B, Montalescot G, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Leite-Moreira A, Vincent J, Rossignol P, Zannad F (2018) Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial. Clin Res Cardiol Ger 107:1192\u20131195","journal-title":"Clin Res Cardiol Ger"},{"key":"1500_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","volume":"75","author":"G Klappacher","year":"1995","unstructured":"Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG et al (1995) Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75:913\u2013918","journal-title":"Am J Cardiol"},{"key":"1500_CR8","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","volume":"65","author":"B Lopez","year":"2015","unstructured":"Lopez B, Gonzalez A, Ravassa S, Beaumont J, Moreno MU, San Jose G, Querejeta R, Diez J (2015) Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65:2449\u20132456","journal-title":"J Am Coll Cardiol"},{"key":"1500_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","volume":"35","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F, Investigators R and Investigators R (2014) Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. Eur Heart J 35:2295\u20132302","journal-title":"Eur Heart J"},{"key":"1500_CR10","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 102:2700\u20132706","journal-title":"Circulation."},{"key":"1500_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1161\/CIRCRESAHA.109.209809","volume":"105","author":"CA Souders","year":"2009","unstructured":"Souders CA, Bowers SL, Baudino TA (2009) Cardiac fibroblast: the renaissance cell. Circ Res 105:1164\u20131176","journal-title":"Circ Res"},{"key":"1500_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci CMLS 71:549\u2013574","journal-title":"Cell Mol Life Sci CMLS"},{"key":"1500_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/ehf2.12360","volume":"5","author":"K Nagao","year":"2018","unstructured":"Nagao K, Inada T, Tamura A, Kajitani K, Shimamura K, Yukawa H, Aida K, Sowa N, Nishiga M, Horie T, Makita T, Ono K, Tanaka M (2018) Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression. ESC Heart Fail. 5:1044\u20131051","journal-title":"ESC Heart Fail."},{"key":"1500_CR14","first-page":"313182","volume":"105","author":"JP Ferreira","year":"2018","unstructured":"Ferreira JP, Rossignol P, Pizard A, Machu JL, Collier T, Girerd N, Huby AC, Gonzalez A, Diez J, Lopez B, Sattar N, Cleland JG, Sever PS, Zannad F (2018) Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart (British Cardiac Society) 105:313182","journal-title":"Heart (British Cardiac Society)"},{"key":"1500_CR15","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"M Hayashi","year":"2003","unstructured":"Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107:2559\u20132565","journal-title":"Circulation"},{"key":"1500_CR16","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H Izawa","year":"2005","unstructured":"Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112:2940\u20132945","journal-title":"Circulation"},{"key":"1500_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11010-006-2955-5","volume":"293","author":"J Radovan","year":"2006","unstructured":"Radovan J, Vaclav P, Petr W, Jan C, Michal A, Richard P, Martina P (2006) Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem 293:71\u201378","journal-title":"Mol Cell Biochem"},{"key":"1500_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000176705","volume":"85","author":"NB Host","year":"1994","unstructured":"Host NB, Hansen SS, Jensen LT, Husum D, Nielsen JD (1994) Thrombolytic therapy of acute myocardial infarction alters collagen metabolism. Cardiology 85:323\u2013333","journal-title":"Cardiology"},{"key":"1500_CR19","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ejhf.688","volume":"19","author":"P Rossignol","year":"2017","unstructured":"Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 19:792\u2013799","journal-title":"Eur J Heart Fail"},{"key":"1500_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jchf.2017.07.011","volume":"5","author":"A Aimo","year":"2017","unstructured":"Aimo A, Vergaro G, Castiglione V, Barison A, Pasanisi E, Petersen C, Chubuchny V, Giannoni A, Poletti R, Maffei S, Januzzi JL Jr, Passino C, Emdin M (2017) Effect of sex on reverse remodeling in chronic systolic heart failure. JACC Heart Fail. 5:735\u2013742","journal-title":"JACC Heart Fail."},{"key":"1500_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00011-016-0977-3","volume":"65","author":"P Rubis","year":"2016","unstructured":"Rubis P, Wisniowska-Smialek S, Wypasek E, Biernacka-Fijalkowska B, Rudnicka-Sosin L, Dziewiecka E, Faltyn P, Khachatryan L, Karabinowska A, Kozanecki A, Tomkiewicz-Pajak L, Podolec P (2016) Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy. Inflamm Res 65:941\u2013949","journal-title":"Inflamm Res"},{"key":"1500_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ejhf.696","volume":"19","author":"M Gyongyosi","year":"2017","unstructured":"Gyongyosi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, Gonzalez A, Thum T, Diez J, Jaisser F, Pizard A, Zannad F (2017) Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail 19:177\u2013191","journal-title":"Eur J Heart Fail"},{"key":"1500_CR23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0002-9149(99)80251-3","volume":"76","author":"NB Host","year":"1995","unstructured":"Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE (1995) The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 76:869\u2013873","journal-title":"Am J Cardiol"},{"key":"1500_CR24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, (Group ESCSD) (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"1500_CR25","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:e137\u2013e161","journal-title":"Circulation"},{"key":"1500_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119\u2013177","journal-title":"Eur Heart J"},{"key":"1500_CR27","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ejhf.792","volume":"19","author":"A Olivier","year":"2017","unstructured":"Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJV, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A (2017) Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Eur J Heart Fail 19:1186\u20131197","journal-title":"Eur J Heart Fail"},{"key":"1500_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1136\/hrt.2003.018424","volume":"90","author":"AD McGavigan","year":"2004","unstructured":"McGavigan AD, Moncrieff J, Lindsay MM, Maxwell PR, Dunn FG (2004) Time course of plasma markers of collagen turnover in patients with acute myocardial infarction. Heart (British Cardiac Society) 90:1053\u20131054","journal-title":"Heart (British Cardiac Society)"},{"key":"1500_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/eurjhf\/hfp136","volume":"11","author":"C Adamopoulos","year":"2009","unstructured":"Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F (2009) Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 11:1099\u20131105","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01500-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T23:20:10Z","timestamp":1593127210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01500-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01500-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"4 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The EPHESUS and REMINDER trials were sponsored by Pfizer. Dr. Zannad and Dr. Pitt were members of the steering committee for EPHESUS. Dr. Stienen, Ferreira, Zannad and Rossignol are supported by a public grant overseen by the French National Research Agency (ANR) as part of the second \u201cInvestissements d\u2019Avenir\u201d program FIGHT-HF (reference: ANR-15-RHU-0004) and by the French PIA project \u201cLorraine Universit\u00e9 d\u2019Excellence\u201d, reference ANR-15-IDEX-04-LUE, and by the Contrat de plan Etat-lorraine and FEDER lorraine. Dr. Pitt reports consultant fees for Bayer, Astra Zeneca, Sanofi, KBP Biosciences*, Sarfez*, Relypsa\/Vifor*, Tricida*, and Stealth Peptides. He holds a patent for site-specific delivery of eplerenone to the myocardium (US patent # 9931412). All other co-authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}